Procept BioRobotics says Aquablation therapy assigned a Category I code
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Humana, Chipotle, Roku: Trending Tickers
Humana (HUM) stock is under pressure after a US court dismissed the company's case to reverse cuts to Medicare bonus payments. Chipotle (CMG) was upgraded to Outperform from Market Perform by BMO Capital Markets analysts, citing a pickup in sales and profit in the second half of the yer. JPMorgan analysts are bullish on Roku (ROKU) ahead of the company's earnings report. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts here. Now let's get to some of today's trending tickers. We're watching Humana, Chipotle, and Roku. And our senior market reporter, Ali Canal, is still with us live from the Nasdaq. First up, let's get to Humana. It's falling after losing a lawsuit over Medicare payments. It's going to cost the company. The health insurer sued to try to undo cuts to its Medicare bonus payments, hoping to restore billions of dollars in revenue. The government had lowered Humana's quality rating, which means the company gets less money for Medicaid, starting in 2026. A Texas court voted to dismiss the case. Down 2% here is what we're seeing for Humana shares. And Ali, we've also seen some pressure on other companies within this industry. Yeah, if you take a look at some of those competitors in the space, Elevance Health, Molina Health, they are also under pressure today. At last check, I believe they're both down around 5%. Now, Humana, like you said, is down over 2%. We are a little bit higher than some of those session lows here. But the decision has been a setback in what was a really high stakes legal case, one that could have added billions to Humana's bottom line, like you mentioned, Julie. And digging into this, it was interesting because the challenge was this downgrade to its Medicare quality ratings. Now, this would have reduced the number of members in bonus-eligible plans. And that's a big deal because these star ratings, they help determine how much money insurers receive in bonuses. And for Humana, that's core to their business. In 2024 alone, they took in 2.5 billion from these payments. And according to Barclays, a win could have added nearly double to Humana's 2026 profit outlook. But the judge ultimately ruled that this case was premature, suggesting that the company needs to complete the administrative appeals process first. But just really underscores the broader challenges here facing some of these government-backed insurance programs. Yeah, definitely. And we could so we could see that process continue by the way legally, so this this story might not be over. Uh, coming up next, let's talk about Chipotle. It's getting an upgrade to outperform from market perform at BMO Capital Markets. The analyst there saying the restaurant chain's sales and profit should pick up in the second half of the year and that the U.S. expansion still has lots of room to grow. The firm setting a $65 price target, implying 21% upside for the shares. The shares, Ali, not getting that much of a lift from this call. Yeah, we're just up around 4/10 of a percent, and it's really the second half that BMO is focused on. They pointed to accelerated same-store sales, improving margins. Uh, the analyst noted that comps are starting to pick up and says that Chipotle's U.S. heavy growth strategy could eventually hit a 10% annual pace. Now, what's was interesting in this note is they also said Chipotle's well-positioned even if the economy slows. And we've been talking about the state of the consumer, and there seems to be two different camps here: the high-income consumer and those that are still struggling with inflation. And that's hit a lot of those consumer-facing names, a lot of these fast food chains. Chipotle shares, by the way, they're down about 11% since the start of the year. And I'm used to talking about how bullish people are about Chipotle. So, we've definitely seen a slowdown on that front. But BMO is saying that its value proposition is best in class, which could help the brand continue to outperform peers on traffic along with revenue. So perhaps this call is a turning point for this company, but like you were saying, we're not seeing too much of a share react to it right now. No, not at the moment. Um, and finally, let's get to another analyst call. JP Morgan bullish on Roku heading into earnings. The firm says advertising's holding up, China tariffs are cooling off, both of which are positive for the company. So, the analyst sees about 10% upside from the stock's last close. This one, um, kind of your bread and butter as somebody who who has covered media here, Ali. Um, and it's a stock that has had an interesting trajectory. Interesting trajectory, especially within this market environment. If you take a look at a year-to-date chart, you'll see right around March and April where a lot of economists were coming out calling for recessions, Roku took a very serious hit. And that's because during any economic slowdown, what's first to go? It's those ad budgets, and that is really core to Roku's business. So, we saw the stock take a hit there. But now, we're up over 20%. And a big reason why is we had a lot of that uncertainty evaporate just a bit from this market. Uh uh, their economy right now seems to be really solid. A recession is not the base case at this point. And JP Morgan is expecting, heading into this earning season, that Roku is going to be in a strong position. They said that they were too conservative last quarter, and they now see platform revenue rising 15% in Q2. That's above current guidance. Full year EBITDA also expected to come in slightly ahead of forecast there. So, we'll see if this name can deliver. But a lot of the gains that we're seeing now since the start of the year, that that's stemming from that recovery from those April lows. Ali, thanks so much. Appreciate it. And you can scan the QR code below to track the best and worst performing stocks with Yahoo Finances' Trending Tickers page.
Bloomberg
4 hours ago
- Bloomberg
Humana Loses Bid to Reverse Medicare Bonus Payment Cut
Humana Inc. lost its lawsuit seeking to reverse cuts to its Medicare bonus payments, a blow for the insurer that had hoped the court would restore billions in revenue. A Texas district court ruled in favor of the government's motion to dismiss the case, affirming the Medicare program's downgrade of Humana's quality ratings that's set to squeeze the company's profits in 2026. Humana shares fell as much as 7.5%.
Medscape
5 hours ago
- Medscape
CMS Okays Coverage of Tricuspid TEER, With Caveats
The recent decision by the US Centers for Medicare and Medicaid Services (CMS) to cover tricuspid transcatheter edge-to-edge repair (T-TEER) could help change the model through which physicians think about right-side heart failure, according to one of the clinicians who worked on the trials of the procedure. On July 2, CMS agreed to cover T-TEER for the treatment of tricuspid regurgitation but only through the coverage with evidence development process, which requires procedures to be performed as part of a CMS-approved study. Some comments solicited during the decision process raised concerns T-TEER has not shown clinically meaningful benefit and that the TRILUMINATE pivotal trial did not show a decrease in mortality, tricuspid valve surgeries, or overall hospitalizations compared to medical therapy. 'While we agree that there are evidence gaps that still need to be addressed regarding T-TEER, we believe the evidence overall, while insufficient, is promising enough to allow coverage with evidence development,' CMS said in announcing its decision. The study criteria — all-cause mortality and hospitalizations through a minimum of 24 months — 'strike the appropriate balance between evidence generation and patient access,' the agency said. The patient must have symptomatic tricuspid regurgitation despite optimal medical therapy and be under the care of a heart team that includes a cardiac surgeon, an interventional cardiologist, a heart failure specialist, and an interventional echocardiographer. Shamir Mehta, MD, cardiologist at McMaster University in Hamilton, Ontario, Canada, and an investigator on TRILUMINATE, said the trial provided evidence of benefit. 'The trial showed improvements in quality of life, and that's an important outcome from the patients' perspective,' Mehta said. And TRILUMINATE did see a reduction in heart failure hospitalization at 2 years, he noted. 'Maybe over the longer term, we begin to see that correlating with a reduction in tricuspid regurgitation,' he said. Mehta acknowledged some of the criticisms of TRILUMINATE were valid but said the main issue was some of the assumptions underlying the trial turned out not to be correct. Prior to TRILUMINATE, right heart failure and tricuspid regurgitation were understudied, so the study and the subsequent TRISCEND II trial were designed using the same paradigm for reduction in events that are used for left-sided heart failure, he said. 'We made an assumption that the same outcomes that we observed in mitral regurgitation would also apply to patients with right heart failure,' he said. 'Maybe, the outcomes that we should be looking at with right-sided heart failure should be different.' Patients with left-sided heart failure tend to present with pulmonary edema and require hospitalisation for acute heart failure. While those with right-sided heart failure accumulate fluid in the periphery and are often not admitted to hospital but treated in the clinic with diuretics and develop and are admitted for other complications such as renal failure. 'There are two types of heart failure, and they can present in very different ways,' Mehta said. The trials that will be conducted under the CED process should help to clarify those differences, and lead to a better understanding of when T-TEER is the right choice for a patient. 'This is an evolving area and we're learning more as we have more randomized trials,' he said. Mehta is an investigator on the TRILUMINATE and CLASP TR trials.
